- Joined
- Nov 2, 2006
- Messages
- 1,047
I don't know if this has been posted before but it's a very interesting study:
http://www.ccfa.org/printview?pageUrl=/reuters/probiotic
http://www.pnas.org/gca?gca=pnas;0804812105v1&submit=Get+All+Checked+Abstracts
Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients
F. prausnitzii exhibits anti-inflammatory effects on cellular and TNBS colitis models, partly due to secreted metabolites able to block NF-κB activation and IL-8 production. These results suggest that counterbalancing dysbiosis using F. prausnitzii as a probiotic is a promising strategy in CD treatment.
http://www.ccfa.org/printview?pageUrl=/reuters/probiotic
http://www.pnas.org/gca?gca=pnas;0804812105v1&submit=Get+All+Checked+Abstracts
Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients
F. prausnitzii exhibits anti-inflammatory effects on cellular and TNBS colitis models, partly due to secreted metabolites able to block NF-κB activation and IL-8 production. These results suggest that counterbalancing dysbiosis using F. prausnitzii as a probiotic is a promising strategy in CD treatment.
Last edited: